Lobbying Information
Subject Matters
- Economic Development
- Employment and Training
- Health
- Industry
- Intellectual Property
- Internal Trade
- Research and Development
- Science and Technology
Subject Matter Details
Grant, Contribution or Other Financial Benefit
- Strategic Innovation Fund, as it relates to any initiative submitted or supported.
Legislative Proposal, Bill or Resolution
- Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection
- Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
- Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade
- Food and Drugs Act and Regulations, as they relate to the establishment of an approval framework for subsequent entry biologic products
- Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products
- Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products
- House of Commons Standing Committee of Health's (HESA) as it relates to Pharmacare, rare disease and/or any other pertinent legislative proposal before the committee
- Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property, approval for therapeutic products, changes to modernize the Right of Appeal
- Patent Act as it relates to changes affecting term restoration or Canada's Access to Medicines Regime
- Patented Medicines Prices Review Board (PMPRB), as it relates to reporting requirements, pricing guidelines, and dispute resolution
- United States, Mexico, Canada Agreement (USMCA) and pharmaceutical intellectual property protection.
Policies or Program
- Biologics and Genetic Therapies Directorate as it relates to policies affecting the review and approval of submissions
- Clinical Trials environment in Canada: operational issues, investment, enrollment
- Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
- Innovation Agenda - as it relates to the Life Science Industry and the Federal Initiative lead by Innovation, Science, Economic Development
- National Pharmaceutical Strategy and negotiation of the Health Accord, as it relates to National Pharmacare/universal or catastrophic drug coverage, Drug policies & Pricing.
- Pandemic Planning as it relates to the Task Group on Antiviral Prophylaxis recommendations
- Policies related to Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors; Information and Submission requirements for SEBs, regulations and intellectual property policies, naming conventions
- Policies related to rare disease as it relates to separate regulatory pathway for drugs for rare diseases and government strategies.
- Policies related to the importation of pharmaceuticals from Canada to the United States
Policies or Program, Regulation
- Orphan Drug Regulatory Framework as it relates to separate regulatory pathway for drugs for rare diseases
Regulation
- Health Canada/PMPRB proposed regulation changes to the Patented Medicines Regulations.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Canadian Institutes of Health Research (CIHR)
-
Environment and Climate Change Canada (ECCC)
-
Federal Economic Development Agency for Southern Ontario (FedDev)
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
National Research Council (NRC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Services and Procurement Canada (PSPC)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Hoffmann-La Roche Limited deals with the healthcare system in the prevention, screening, diagnosis, treatment and management of acute and long-term disease and supports leading research and development - including clinical research, clinical trials and genetic research.
Responsible officer name and position during the period of this registration
RONNIE MILLER,
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
7070 Mississauga Road
Mississauga, ON L5N 5M8
Canada
Telephone number:
905-542-5555
Parent Company Information
- F. Hoffmann-La Roche AG
-
Grenzacherstrasse 124
4070 Basle
Switzerland
Subsidiary Beneficiary Information
Hoffmann-La Roche Limited does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Matthew Bureau,
Healthcare Systems Partner |
No public offices held
- Michele D'Elia,
Executive Director, Medical & Scientific Affairs |
No public offices held
- Andrew Plank,
President & General Manager, Roche Diagnostics |
No public offices held
- Dvorah Richler,
Strategic Healthcare Partner |
No public offices held
- Roger Tam,
Vice President, Legal |
No public offices held
- Carlene Todd,
Vice President, Access |
No public offices held
- Bill Zindle,
Executive Director, Strategy and Marketing |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Logan Caragata,
Head, Healthcare System Strategy & Government Affairs |
No public offices held
- Francois Drolet,
Executive Director, Access, Policy & Government Relations |
No public offices held
- Cassondra McCrory,
Healthcare System Partner, Federal |
No public offices held
